Document registry — page 15
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Consultation on the draft synthesis of incretin receptor agonists for metabolic dysfunction-associated steatohepatitis. The anchor outcome is histological, which raises…
12 Jul 2026 -
Event-driven cardiovascular outcome trial, phase 3 study of Survodutide in cardiovascular and obesity over event-driven. The Institute holds no reported primary result…
11 Jul 2026 -
Consultation on the draft certainty index, a cross-cutting finding aid that lists every assessed outcome in the document set by its certainty rating. The index makes it…
10 Jul 2026 -
Consultation on the draft monograph for orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist. The draft assesses a compound whose phase 3 programme…
06 Jul 2026 -
Consultation on the draft monograph for SS-31 (elamipretide), which the assessment committee released for public comment before ratification. The draft grades the…
04 Jul 2026 -
Consultation on the draft of CEI-MS-13, which specifies the performance a determination must achieve for method validation and states what the resulting figure does not…
04 Jul 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide compared with the comparator…
High04 Jul 2026 -
Consultation on the draft monograph for Sermorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
03 Jul 2026 -
What randomised human evidence exists for BPC-157 in any indication?
Very low03 Jul 2026 -
Consultation on the draft monograph for KPV, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
02 Jul 2026 -
Consultation on the draft monograph for Pramlintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
30 Jun 2026 -
Consultation on the draft monograph for PT-141 (bremelanotide), which the assessment committee released for public comment before ratification. The draft grades the…
30 Jun 2026 -
Consultation on the draft standard for freeze–thaw and in-use stability assessment of reconstituted peptide solutions. The draft specifies the cycling regime, the hold…
26 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over 76 weeks. The Institute holds no reported primary result…
26 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, is the effect of Exenatide maintained across the full duration of…
High25 Jun 2026 -
Record of documents ratified in the 2026 Q2 assessment cycle.
22 Jun 2026 -
Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue). Mazdutide reproduces the natural dual activity of oxyntomodulin with a pharmacokinetic profile suitable for weekly dosing. The glucagon arm…
Moderate22 Jun 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High18 Jun 2026 -
Freeze–thaw and in-use stability assessment of reconstituted peptide solutions
High16 Jun 2026 -
Growth-hormone-releasing hormone fragment analogue. Sermorelin stimulates pituitary growth-hormone release through the GHRH receptor. Its very short half-life confines the pharmacodynamic effect to a…
Low15 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low15 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate12 Jun 2026 -
Peptides, SARMs, injectable oils and raw materials. Long-established synthesis operation.
12 Jun 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of Thymosin beta-4 compared with the comparator used in its contributing…
Low10 Jun 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its…
Moderate09 Jun 2026 -
Peptides and SARMs with a global warehouse network. Trades as Homopeptide.
07 Jun 2026 -
Consultation on the draft monograph for Lixisenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
06 Jun 2026 -
Consultation on the draft of CEI-MS-04, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
05 Jun 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141…
Moderate05 Jun 2026 -
Determination of peptide content and its distinction from chromatographic purity
High04 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor…
High02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Lixisenatide compared with its comparator?
High31 May 2026 -
Endogenous nonapeptide. DSIP was isolated on the hypothesis that it mediated sleep induction. Subsequent work has not established a receptor, a consistent pharmacological…
Very low24 May 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate22 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low22 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High21 May 2026 -
How much does a reported chromatographic purity figure vary with the method used to obtain it?
High20 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its…
High19 May 2026
page 15 of 41